Ashleigh M. Fordham

Ashleigh M. Fordham

Auto-generated profile, based on publicly available information

Ashleigh M. Fordham

Children’s Cancer Institute 1 , Lowy Cancer Research Centre, UNSW Sydney, Sydney, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Current Problems in Cancer
Verified
Journal Article
Closed access
PMPriya Mahajan
Priya Mahajan
MCMichela Casanova
Michela Casanova
AFAndrea Ferrari
Andrea Ferrari
AFAshleigh Fordham
Ashleigh Fordham
TTToby Trahair
Toby Trahair
RVRajkumar Venkatramani
Rajkumar Venkatramani

1 December 2019 in JCO Precision Oncology
Verified
Journal Article
Open access
TTToby Trahair
Toby Trahair
AGAndrew J. Gifford
Andrew J. Gifford
AFAshleigh Fordham
Ashleigh Fordham
CMChelsea Mayoh
Chelsea Mayoh
MFMitali Fadia
Mitali Fadia
KMKaren L. MacKenzie
Karen L. MacKenzie
PURPOSE: Before anaplastic lymphoma kinase (ALK) inhibitors, treatment options for ALK-positive inflammatory myofibroblastic tumors (AP-IMTs) were unsatisfactory. We retrospectively analyzed the outcome of patients with AP-IMT treated with crizotinib to document response, toxicity, survival, and features associated with relapse. METHODS: The cohort comprised eight patients with AP-IMT treated with crizotinib and surgery. Outcome measures were progression-free and overall survival after commencing crizotinib, treatment-related toxicities, features associated with relapse, outcome after relapse, and outcome after ceasing crizotinib. RESULTS: The median follow-up after commencing crizotinib was 3 years (range, 0.9 to 5.5 years). The major toxicity was neutropenia. All patients responded to crizotinib. Five were able to discontinue therapy without recurrence (median treatment duration, 1 year; range, 0.2 to 3.0 years); one continues on crizotinib. Two critically ill patients with initial complete response experienced relapse while on therapy. Both harbored RANBP2-ALK fusions and responded to alternative ALK inhibitors; one ultimately died as a result of progressive disease, whereas the other remains alive on treatment. Progression-free and overall survival since commencement of crizotinib is 0.75 ± 0.15% and 0.83 ± 0.15%, respectively. CONCLUSION: We confirm acceptable toxicity and excellent disease control in patients with AP-IMT treated with crizotinib, which may be ceased without recurrence in most. Relapses occurred in two of three patients with RANBP2-ALK translocated IMT, which suggests that such patients require additional therapy.

15 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
AMAngelica M. Merlot
Angelica M. Merlot
Sumit SahniSumit Sahni
Sumit Sahni
DLDarius Lane
Darius Lane
AFAshleigh M. Fordham
Ashleigh M. Fordham
NPNamfon Pantarat
Namfon Pantarat
DKDanuta S. Kalinowski
Danuta S. Kalinowski
Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) demonstrates potent anti-cancer activity. We previously demonstrated that 14C-Dp44mT enters and targets cells through a carrier/receptor-mediated uptake process. Despite structural similarity, 2-benzoylpyridine 4-ethyl-3-thiosemicarbazone (Bp4eT) and pyridoxal isonicotinoyl hydrazone (PIH) enter cells via passive diffusion. Considering albumin alters the uptake of many drugs, we examined the effect of human serum albumin (HSA) on the cellular uptake of Dp44mT, Bp4eT and PIH. Chelator-HSA binding studies demonstrated the following order of relative affinity: Bp4eT≈PIH>Dp44mT. Interestingly, HSA decreased Bp4eT and PIH uptake, potentially due to its high affinity for the ligands. In contrast, HSA markedly stimulated Dp44mT uptake by cells, with two saturable uptake mechanisms identified. The first mechanism saturated at 5-10 µM (B max:1.20±0.04 × 107 molecules/cell; K d:33±3 µM) and was consistent with a previously identified Dp44mT receptor/carrier. The second mechanism was of lower affinity, but higher capacity (B max:2.90±0.12 × 107 molecules/cell; K d:65±6 µM), becoming saturated at 100 µM and was only evident in the presence of HSA. This second saturable Dp44mT uptake process was inhibited by excess HSA and had characteristics suggesting it was mediated by a specific binding site. Significantly, the HSA-mediated increase in the targeting of Dp44mT to cancer cells potentiated apoptosis and could be important for enhancing efficacy.

20 July 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
AFAshleigh M. Fordham
Ashleigh M. Fordham
JXJinhan Xie
Jinhan Xie
AGAndrew J. Gifford
Andrew J. Gifford
CWCarol Wadham
Carol Wadham
LMLisa T. Morgan
Lisa T. Morgan
TTToby Trahair
Toby Trahair
Background: Epithelioid inflammatory myofibroblastic sarcoma (eIMS) is characterised by perinuclear ALK localisation, CD30 expression and early relapse despite crizotinib treatment. We aimed to identify therapies to prevent and/or treat ALK inhibitor resistance.Methods: Malignant ascites, from an eIMS patient at diagnosis and following multiple relapses, were used to generate matched diagnosis and relapse xenografts.Results: Xenografts were validated by confirmation ofRANBP2-ALKrearrangement, perinuclear ALK localisation and CD30 expression. Although brentuximab-vedotin (BV) demonstrated single-agent activity, tumours regrew during BV therapy. BV resistance was associated with reduced CD30 expression and induction of ABCB1. BV resistance was reversed in vitro by tariquidar, but combination BV and tariquidar treatment only briefly slowed xenograft growth compared with BV alone. Combining BV with either crizotinib or ceritinib resulted in marked tumour shrinkage in both xenograft models, and resulted in prolonged tumour-free survival in the diagnosis compared with the relapse xenograft.Conclusions: CD30 is a therapeutic target in eIMS. BV efficacy is limited by the rapid emergence of resistance. Prolonged survival with combination ALK and CD30-targeted-therapy in the diagnosis model provides the rationale to trial this combination in eIMS patients at diagnosis. This combination could also be considered for other CD30-positive,ALK-rearranged malignancies.

2 July 2026
Verified
Other
Open access
AFAshleigh M. Fordham
Ashleigh M. Fordham
LBLauren M. Brown
Lauren M. Brown
CMChelsea Mayoh
Chelsea Mayoh
ASAlice Salib
Alice Salib
ZBZara A. Barger
Zara A. Barger
EFEmmy D.G. Fleuren
Emmy D.G. Fleuren
A) PDGFA-D ligand RNA expression (TPM) across sarcoma samples, rank ordered on total PDGF-expression counts. RNA expression (Z-score) for B) PTK7, C) FGFR4 and D) FGF8 in the ZERO cohort. Colors indicate specific samples as shown in legends. E-F) Correlation between E) FGFR4 (TPM) and FGFR4 copy number, or F) FGF8 (TPM) and FGF8 copy number in ZERO sarcoma patients. G) Gene set enrichment analysis (GSEA) was performed using the camera method (limma package, R) on the full transcriptomic dataset to compare FP-RMS with other sarcoma subtypes. Pathway definitions were obtained from the Reactome gene set collection (reactome.org). The analysis was conducted using default parameters and significance was assessed based on FDR-adjusted p-values. H) Heatmap illustrating single sample GSEA (ssGSEA) scores for individual sarcoma patient samples from the three FGFR4 pathways identified from (G). Colors indicate specific samples as shown in legends. EWS: Ewing sarcoma, FP-RMS: fusion-positive rhabdomyosarcoma, FN-RMS: fusion-negative rhabdomyosarcoma, OS: osteosarcoma, MRT: malignant rhabdoid tumor, MPNST: malignant peripheral nerve sheath tumor, ASPS: alveolar soft part sarcoma, AS: angiosarcoma, IFS: infantile fibrosarcoma, DSRCT: desmoplastic small round blue cell tumor, GIST: gastrointestinal stromal tumor, SynS: synovial sarcoma, GNET: gastrointestinal neuroectodermal tumor, HGU: high-grade undifferentiated sarcoma, AF: ameloblastic fibrosarcoma, CIC: CIC-rearranged sarcoma, EPI: epithelioid sarcoma, FMX: low-grade fibromyxoid sarcoma, Round cell: EWSR1-PATZ1 round cell sarcoma, desmoid: desmoid tumor.

2 July 2026
Verified
Other
Open access
AFAshleigh M. Fordham
Ashleigh M. Fordham
LBLauren M. Brown
Lauren M. Brown
CMChelsea Mayoh
Chelsea Mayoh
ASAlice Salib
Alice Salib
ZBZara A. Barger
Zara A. Barger
EFEmmy D.G. Fleuren
Emmy D.G. Fleuren
Images captured of Rh30 FP-RMS cells at 76h after treatment with serial dilutions of AZD4547, erdafitinib, FGF401, lenvatinib or ponatinib, at 10x magnification, unfiltered.